U.S. Biotech Stock News

How Trip.com Group stock has been trading recently Trip.com Group (TCOM) has seen mixed share performance, with a 0.8% move over the past day, contrasted with weaker returns over the week, month and past 3 months as investors reassess travel exposure. See our latest analysis for Trip.com Group. At a share price of $61.77, Trip.com Group’s recent 7 day share price return of an 18.36% decline and year to date share price return of a 17.08% decline contrast with a 3 year total shareholder return...

If you are wondering whether AdaptHealth's share price lines up with its underlying worth, you are not alone. This article focuses squarely on what the current price might be implying about value. The stock last closed at US$10.61, with returns of 1.1% over 7 days, 1.2% over 30 days, 9.7% year to date and 0.9% over 1 year. These figures are set against much weaker 3 year and 5 year returns of 49.5% and 72.1% declines. Recent coverage has focused on AdaptHealth's position in the home...

If you are wondering whether Driven Brands Holdings is attractively priced at its current level, this article walks through the numbers so you can judge the value story for yourself. The share price closed at US$15.52 most recently, with returns of 1.1% over the last 30 days, 7.0% year to date, and a 2.4% decline over the past year, alongside deeper 3 year and 5 year declines of 43.3% and 47.9%. Recent moves in the stock have drawn attention back to how the company is positioned in auto...

Paylocity Holding (PCTY) is back on investor radars after BTIG’s Allan Verkhovski initiated coverage with a Buy rating, alongside broadly positive brokerage sentiment and references to the company’s fundamental strength and recent technical stabilization. See our latest analysis for Paylocity Holding. At a share price of $140.10, Paylocity has seen a 7 day share price return of 6.84% and a year to date share price return of 3.84% decline, while the 1 year total shareholder return of 28.88%...

Recent performance snapshot for Amer Sports Amer Sports (NYSE:AS) has caught investor attention after a mixed run, with the share price showing a small 1 day decline and a modest pullback over the past week and month. At the same time, the stock has delivered a positive total return over the past 3 months and past year, inviting closer scrutiny of how recent performance lines up with the company’s current fundamentals. See our latest analysis for Amer Sports. That recent 1 day and 7 day share...

If you have been wondering whether US Foods Holding is priced fairly or not, this article walks through what the current share price might imply about its value. The stock last closed at US$85.71, with returns of 13.4% over the past 7 days, 11.2% over 30 days, 14.8% year to date, 25.5% over 1 year, 133.9% over 3 years and 146.5% over 5 years, which may catch the eye of investors thinking about what is already priced in. Recent attention on US Foods Holding has focused on how the business is...

Itron (ITRI) is back in the headlines after announcing a multi year collaboration with Thessaloniki based EYATH S.A. to deploy Smart Water Solutions across the Greek utility's network. See our latest analysis for Itron. For context, Itron's share price is now at $100.04, with a 30 day share price return of 5.68% and a year to date share price return of 5.90%. The 1 year total shareholder return is a 5.05% decline and the 3 year total shareholder return is 76.13%, suggesting long term holders...

If you are wondering whether CrowdStrike Holdings is still worth the price on the screen today, the key question is how that price compares to a fair assessment of its value. The stock last closed at US$453.88, with a 7 day return of a 3.6% decline, a 30 day return of a 3.4% decline, and a 1 year return of 27.1%. It is roughly flat year to date at 0.1% and shows a very large 3 year return that is around 3x. Recent headlines around CrowdStrike continue to highlight its role in cybersecurity...

Why the new rate hike opposition matters for Consolidated Edison (ED) Officials representing about 9 million New Yorkers are urging regulators to reject Consolidated Edison (ED) rate hikes for 2026 to 2028. They argue that even reduced electricity and gas increases strain households and small businesses. See our latest analysis for Consolidated Edison. Consolidated Edison’s share price has moved to $103.81, with a 1-day share price return of 1.20% and a 7-day share price return of 4.64%,...

OneMain Holdings (OMF) moved into focus after JP Morgan cut its rating from Neutral to Underweight. The call was centered on rising credit card and auto delinquencies among non prime borrowers. See our latest analysis for OneMain Holdings. The downgrade came after a sharp 5.1% drop, and that negative reaction is now sitting alongside a 7 day share price return of 7.73% and a 30 day share price return of 3.77% at a last close of US$65.40. Even so, the 90 day share price return of 20.82% and 1...

If you have been wondering whether Ally Financial's current share price offers real value or just headline appeal, this breakdown is designed to give you a clear, practical view. The stock closed at US$43.61, with returns of 22.0% over 1 year and 54.5% over 3 years, while the last 7 days and year to date show declines of 4.6% and 4.7% respectively. Recent coverage around Ally Financial has focused on its position as a listed diversified financials company, as investors weigh its exposure to...

If you are looking at Microchip Technology and wondering whether the current share price lines up with its underlying worth, you are not alone. The stock last closed at US$74.70, with recent returns of 16.7% over 30 days, 14.9% year to date, and 32.9% over the past year, although the 7 day return was a 0.7% decline. Recent interest around Microchip Technology has focused on how a well known semiconductor name fits into investor portfolios that are increasingly sensitive to price and quality...

FDA Breakthrough Therapy Designation: Why It Matters for Investors The latest move around Revolution Medicines (RVMD) is the FDA granting Breakthrough Therapy Designation to its RAS(ON) G12D inhibitor zoldonrasib for certain previously treated advanced non small cell lung cancer patients. See our latest analysis for Revolution Medicines. The Breakthrough Therapy news arrives after a period of sharp share price swings, with Revolution Medicines now trading at $120.28 and posting a 30 day share...

If you are wondering whether Extreme Networks is priced attractively today, the key question is whether the current US$15.96 share price still lines up with what the business is actually worth. The stock has risen 2.2% over the last 7 days, although returns over 30 days, year to date and the past year sit at 4.1%, 3.5% and 7.9% declines respectively. This may signal changing views on its potential and risks. Recent coverage of Extreme Networks has focused on how investors are reassessing...

Airbnb (ABNB) is back in focus after hiring Ahmad Al-Dahle, a former Meta generative AI leader, as Chief Technology Officer, a move investors are watching closely for its impact on AI powered travel services. See our latest analysis for Airbnb. The appointment of Ahmad Al-Dahle comes as Airbnb’s share price, at US$130.66, reflects mixed momentum, with a 7 day share price return of 6.18% and a 90 day share price return of 3.77%. The 1 year total shareholder return of 3.30% contrasts with a 5...

In recent days, LendingClub has emerged as one of the stronger performers among smaller banks after reporting improved quarterly earnings and revenue, drawing investor attention amid weakness in several large U.S. bank stocks. The company’s standing as a high-growth momentum breakout candidate, supported by upbeat analyst estimate revisions and supportive technical trends, has differentiated it from many traditional bank peers. Against this backdrop of stronger short-term earnings momentum,...

If you are wondering whether W.W. Grainger at around US$1,068.72 is priced for strength or stretched, you are not alone. This article is built to help you frame that question clearly. The stock has returned 3.8% over the last 7 days, 4.8% over the last 30 days, 6.5% year to date, but shows a 3.2% decline over the last year, while longer periods such as 3 years and 5 years sit at 96.0% and 187.0% respectively. Recent coverage of W.W. Grainger has centered on its role as a key industrial...

Why Signet Jewelers is on investors’ radar today Signet Jewelers (SIG) has drawn investor attention after recent share price moves, with the stock up 1.7% over the past day, 12.8% over the past week, and 14.3% over the past month. See our latest analysis for Signet Jewelers. The recent 1 month share price return of 14.3%, alongside a year to date share price return of 10.5%, sits against a 1 year total shareholder return of 68.4%. This suggests momentum has been stronger over the longer...

KKR (KKR) shares recently moved after a fresh look at the firm’s fundamentals, with investors weighing its recent returns, revenue and net income figures against the current share price of US$131.42. See our latest analysis for KKR. At the current share price of US$131.42, KKR’s recent 11.75% 90 day share price return contrasts with a 16.12% decline in 1 year total shareholder return. However, 3 year and 5 year total shareholder returns of 152.89% and 241.62% point to stronger longer term...

If you are trying to figure out whether Unity Software's current share price still makes sense, you are not alone. This article focuses squarely on what you are paying versus what you might be getting. The stock closed at US$40.95 and has seen a 1 year return of 88.1%, even though the last 7 days, 30 days, and year to date show returns of an 8.3% decline, 6.5% decline, and 7.5% decline respectively. Recent attention on Unity has been driven by ongoing interest in its software platform and...

In mid-January 2026, several major brokerages, including BofA Securities, Barclays, Scotiabank, and UBS, updated their views on Americold Realty Trust and the cold storage REIT segment, reshaping investor expectations for the business. The mix of cautious sector commentary alongside recognition of Americold’s expanding global temperature-controlled warehousing footprint offers a more nuanced picture of its longer-term prospects. We’ll now examine how this cluster of analyst revisions,...

BioCryst Pharmaceuticals (BCRX) recently issued full year 2026 earnings guidance, telling investors it expects total revenue between US$635 million and US$660 million, a data point that now anchors many discussions around the stock. See our latest analysis for BioCryst Pharmaceuticals. Even with the fresh 2026 revenue guidance and a slot at the J.P. Morgan Healthcare Conference, BioCryst Pharmaceuticals’ recent trading has been weak, with a 1 day share price return of 7.11% and a 7 day share...

In mid-January 2026, authID announced an integration with ServiceNow to bring secure, biometric identity verification into more than 8,400 ServiceNow-powered contact centers worldwide, including those used by most Fortune 500 companies, aiming to reduce fraud and strengthen audit trails for high-risk account changes and transactions. This move, coming alongside ServiceNow’s appointment of former Microsoft Chief Legal Officer Hossein Nowbar, underscores a broader push to reinforce trust,...

Earlier in January 2026, Littelfuse announced that Executive Vice President, Mergers & Acquisitions, Chief Legal Officer and Corporate Secretary Ryan K. Stafford will separate from the company effective April 30, 2026, while also preparing to release its fourth-quarter 2025 results on January 28, 2026. These leadership changes and upcoming earnings come as analysts highlight Littelfuse’s push into power semiconductors and EV charging infrastructure amid a broadly upbeat semiconductor...